Core Viewpoint - Mees Health (02415.HK) announced that its subsidiary, Shanghai Mees Pharmaceutical Technology Co., Ltd., has won a large real-world research project from a Chinese pharmaceutical company, focusing on the efficacy and safety of IL-1β monoclonal antibody treatment for gout patients [1] Group 1 - The project aims to systematically evaluate the effectiveness and safety of IL-1β monoclonal antibody treatment for patients during both acute and intercritical phases of gout through a combination of prospective and retrospective observational studies [1] - The project is valued at approximately RMB 21 million [1] - The group leverages over a decade of experience in its internet doctor platform, utilizing big data and artificial intelligence technologies to connect doctors, patients, and medical device companies, thereby providing digital solutions to enhance the healthcare ecosystem and improve medical quality [1]
梅斯健康(02415.HK)：中标中国某药企「痛风智管计划」大型真实世界研究项目